SRPT

ACCE thesis

Sarepta develops gene therapies and RNA-based treatments for Duchenne muscular dystrophy (DMD), with ELEVIDYS-its one-time AAV gene therapy approved in June 2023-as the commercial centerpiece of the franchise. DMD is a rare, fatal pediatric disease with no meaningful competition in the gene therapy space, giving Sarepta pricing power that's structurally protected by the complexity of manufacturing and the orphan drug designation. ELEVIDYS is the near-term engine: the expanded label covering ambulatory patients ages 4 and up opens a patient population Sarepta estimates at roughly 4,000-8,000 eligible boys in the U.S., and early commercial execution has been the sole variable separating the stock from a very different valuation story. The forward PE of 6.2x against a trailing 48.5x tells you the market is pricing in a dramatic earnings ramp-one that depends entirely on ELEVIDYS uptake accelerating through 2025 as payer coverage decisions solidify and treatment centers build capacity. At $1.8B market cap, the stock has been destroyed from its highs, which creates a binary setup: either commercial penetration inflects over the next two to three quarters, or the bear case-that gene therapy logistics and $3.2M list price friction are structural headwinds-proves correct.

• severe
  Extreme short interest

  Short interest at 28.3% of float signals deep market skepticism; combined with ACCE momentum score of 25/100, squeeze or collapse risk is elevated.
• high
  Negative gross margin

  Gross margin of -6.5% means Sarepta is losing money on every dollar of revenue before any operating expenses, a fundamental profitability concern.
• high
  Revenue contraction

  Revenue declined -1.9% YoY, a sharp reversal from the 5-year CAGR of 33.1%, suggesting the growth story may be stalling.
• high
  Elevated leverage

  Debt/Equity of 69.57 is extremely high; with a negative gross margin, servicing this debt load poses meaningful financial risk.
• moderate
  Depressed ACCE score

  Overall ACCE score of 36/100, with momentum at 25/100 and growth at 5/100, reflects broad deterioration across key investment quality dimensions.

Snapshot